Chemical and Biological Defense Program - EMD

Continue Engineering Manufacturing Development activities with selected performer(s) to include analytical testing and clinical testing of prototype.

Continue efforts to produce additional data to better assess detection, protection, and hazard mitigation capabilities against chemical, biological, toxic, and other threats. Conduct workshops on understanding advanced and emerging threat priorities to align with the CBDP. Conduct market surveys and assessments of technologies for rapid…

Initiate AVCAD capability expansion to include Pharmaceutical Based Agents (PBA). Modify the contract to include algorithm development for the PBA, updating logistics products and support of verification testing. Continue program management, administrative processes and Other Government Agency (OGA) support for logistics and test support.

Efforts support advanced experimentation activities with joint warfighters to identify CB defense capability gaps across the services. As part of a coordinated experimentation campaign, the program will use BA5 to verify, validate, and integrate physiological monitoring software capabilities into the hardware-focused decision support…

Efforts support advanced experimentation activities with joint warfighters to identify chemical and biological (CB) defense capability gaps across the services. FY 2027 efforts integrates software capabilities developed under the CB WEARABLES program line with additional tactical, readiness, and performance monitoring functions…

Perform required testing in coordination with evaluator's to assess capability set one of Commercial Off-the-Shelf (COTS) systems to meet the requirements. Support program management and administration processes to include but not limited to program oversight, resource justification, budgeting and programming, milestone and schedule…

Continued repackaging and integration of Standoff detection, cross platform teaming and upgrades to autonomous chemical and biological (CB) mapping in denied Global Positioning System (GPS) operations for UASs, at part of Capability Set 3.0. Initiated command and control integration, sensor integration for backpack portable UASs, and…

Complete all developmental test and operational test (DT/OT) efforts, operational assessment, and Milestone C (MS C) Army Test and Evaluation Center evaluation report. Prepare documentation for phase four Low Rate Initial Production (LRIP) and MSC in 4Q FY 2027 with a LRIP contract award in 1Q FY 2028. Continue Program management and…

Continue development/expansion of well-characterized, traceable biological threat agent assays, reference materials and vital information for biological defense to known and emerging threats supporting fielded/developmental systems. Continue consolidating requirements across the enterprise to achieve economies of scale and continue to…

Continue expansion of site locations for increased sequencing capabilities to monitor critical assay performance that detect biothreats, and exchange critical data (sequence information) collected at these sites. (One site per year). Continue expanding the repository of collected biothreat genomic information to a government access…

Initiate and award contract actions for maturation of multiple prototype systems, integrate prototypes into a holistic multi-modality approach. Conduct iterative prototyping with developmental test and evaluation on components/sub-components of remote sensing systems, to include CBRN Unmanned Aerial Systems (UAS). Support refinement of…

FFBS Increment 1 completed additional prototype engineering and testing to account for COTS sequencer hardware component product obsolescence. FFBS Increment 1 completed Engineering and Manufacturing Development (EMD) testing on prototypes and prepared for transition into the Production and Deployment phase. Finally, FFBS updated…

FY 2027 BA5 funds will support the down select between up to two FFBS Increment 2 TMRR performers to move into the Engineering and Manufacturing Development (EMD) phase and initiates Developmental Testing / Operational Testing (DT/OT).

Continue engineering, development, and modernization of MFK in support of the time-phased transition of capabilities from MFK to CB Support to command and control.

Continued government strategic planning, systems engineering, logistics, training, technical support, integration, and test and evaluation. Initiated chemical and biological sensor and integrated sensor suite LRIP asset development, and initiate CS2.2 developmental testing.

Complete chemical and biological sensor and overall modular mission payload (previously NBCRV SSU Capability Set 2.2) development and integration efforts of CRMMP LRIP assets. Continue sensor level developmental and operational testing and initiate system level developmental testing. Continue program office management and administration…

Started clinical trials and completed operational assessment.

Food and Drug Administration (FDA) clearance of second and third panels, conduct remainder of Operational Tests for services.

Conduct developmental testing and Initial Operational Test and Evaluation (IOT&E) for Increment II (Software Solutions I/II). Establish the initial laboratory reach back capability for Increment I to enable analysis of genetically engineered biological threats. Collaborate with advanced development partners to test objective agents…

Complete operational testing requirements, to include First Article Test (FAT). Complete product verification testing due to vendor manufacturing optimization. Continue program management and support activities.

Continue developing, prototyping, and maturing SO-P CB technologies to rapidly equip users with capabilities in response to new and emerging threats and opportunities. SPU RCDD develops multiple SO-P CB products that close rapid response gaps and reduce risk across the Enterprise through high risk / high reward advanced development…

Completed integration of WARP prototypes to include interfacing with the Tactical Awareness Kit (TAK) Plug In. Completed development and testing of the hardened prototype.

Completed physical Military Standard (MIL-STD) and end-to-end (integration into USSOCOM equipment) test and evaluation activities. Completed multiple developmental and operational assessments.

FY 2027 will facilitate the transition from WARP requirements to MACE requirements as WARP Increment 2. Increment 2 will continue the development of technologies in support of USSOCOM Theater requirements. Increment 2 will focus on additional personnel chemical exposure edge algorithms, expanding to include additional tactical radios…

Conducted Multi-Service Operational Test & Evaluation (MOT&E) and development test/operational test activities in preparation for Full Rate Production (FRP) decision.

Continued device development of atropine autoinjector. Completed formative human factors study for the atropine autoinjector. Selected formulation method with additional formulation activities ongoing. Initiated Technology Transfer activities and continued batch production of atropine. Delivered devices for military feasibility and…

Continue dose ranging studies in preparation for Good Laboratory Practice (GLP) regulated pivotal efficacy studies

Field multiple data updates to military medical guidelines to support medical rapid response and maintain force regeneration in a chemical or biological emergency. Continue evaluating FDA-approved and/or late-stage products to repurpose as a CB defense MCM.

Field multiple data updates to military medical guidelines to support medical rapid response and maintain force regeneration in a chemical or biological emergency. Continue nonclinical studies to evaluate FDA-approved and/or late-state products to repurpose to treat symptoms from CB threats.

FAMS-S AID is forecasted to enter the Engineering and Manufacturing Development (EMD) Phase at Milestone B as a new variant to the FAMS-S Major Capability Acquisition (MCA) ACAT IV program. Award a competitive request for prototype contracting action and select a candidate technology to mature through the program's lifecycle. Complete a…

Joint Service SEDS continued EMD phase activities to include Laboratory Method Development, Chemical Efficacy contact and vapor testing, Decontamination Enclosure testing, Decontaminant Interoperability, Decontaminant Shelf Life, Power, Protective Equipment Compatibility, and Packaging, Handling, and Transportation Testing. Conducted…

Award the Phase 3 Prototype Contract for the spray systems that will be utilized during EMD. Initiate and complete Critical Design Review, Manufacturing Readiness Assessment, and Systems Verification Review (SRR) / Production Readiness Review (PRR). Initiate and complete DT/OT, including Iterative Warfighter Touchpoints, Reliability &…

Completed all non-clinical model studies in support of transition to Rapid Access Product in Development (RAPID).

Completed all outstanding testing and awarded final prototype contract in order to facilitate the orderly shutdown.

Continued prototype evaluation, and testing of bio mask. Incorporated initial user feedback and evaluations into prototype. Evaluated ocular protection scalability to meet the intent of the Chemical Biological Defense Program 2022 Enhanced Biodefense and Pandemic Preparedness Narrative.

Complete Phase I testing, conduct system down-select, and begin Phase II testing.

Complete Phase I testing, conduct system down-select, and begin Phase II testing.

Continue incremental development of RAPID database and initiate development of classified annexes; release RAPID database updates to stakeholders; continue storage/stability testing for select MCMs; evaluate RAPID operational capability through relevant exercises/ tabletop exercises. Continue developing regulatory documentation for MCMs.

Phase 1 testing will complete and down select to no more than 2 vendors. Exercise contract option to initiate Phase II testing.

Complete Operational Testing (OT) on General Purpose Glove (GPG). Initiate and complete Aviation Glove Heavy (AGH) and GPG analysis and documentation to support AGH Full Rate Production (FRP) in 1Q FY 2027 and GPG FRP in 2Q FY 2027.

Completed all outstanding testing in order to facilitate the orderly shutdown of Engineering and Manufacturing Development (EMD) activities in order to transition program efforts to Next Generation - Individual Protection. Accelerated developmental investments for a future suit.

Continue the development and evaluation of Next Generation Individual Protection (NG IP) prototypes in support of the Joint Service Capability Needs Statement (JSCNS) by completing Phase II testing and beginning Phase III test and evaluation activities, including a Wear Trial.

Phase 2 clinical trial and manufacturing completed, non clinical studies to be completed in 3QFY26. Program transitioning to Joint Product Lead (JPL) Enabling Biotechnologies (EB) Rapid Access Products In Development (RAPID) program by 4QFY26.

Progressed development and testing in safety and efficacy clinical trials of a pan-viral vaccine candidate to protect against respiratory viruses.

FY2027 planned work Continue optimization of in-silico and laboratory testing capabilities in a classified environment. Evaluate classified threats and develop medical countermeasure data products.

FY2026 to FY2027 change Decrease due to efficiency gains and optimization of laboratory and in-silico methods.

FY2026 plans — current year Perform capability demonstration at United States Government (USG) partner facilities to evaluate in-silico and laboratory capabilities in a classified environment.

FY2025 accomplishments Initiated expansion of existing capabilities and establish new testing capabilities as required to support CBD Enterprise. Conducted threat characterization studies and MCM screening studies for prototypes generated by the Generative Unconstrained Intelligent Drug Engineering (GUIDE) program.

FY2025 accomplishments Increase subject matter expertise in the execution of CB survivability requirements for both materiel and non-material solutions. Review and assist in document preparation for milestones and programs reviews. Conduct CB survivability compliance and interoperability reviews for CB on major acquisition efforts for the Joint Force, to include; Combatant Command (CCMD) Deployed Unit Assessment, Foreign Comparative Test (FCT) for Optionally Manned Fighting Vehicle, CB Survivability studies, Nuclear Biological Chemical Reconnaissance Vehicle Sensor Suite Upgrade COEs, Stryker Predictive Maintenance Pilot testing, CB Equipment Prepositioning Assessments, warfighter Integrated Sensor Ensemble…